Tibbi \u018frazi B\u00f6lm\u0259l\u0259rini \u0130dar\u0259etm\u0259 Birliyi (T\u018fB\u0130B) vaksinasiya il\u0259 ba\u011fl\u0131 suallara ayd\u0131nl\u0131q g\u0259tirib.<\/p>\n
H\u0259min m\u0259s\u0259l\u0259l\u0259ri t\u0259qdim edir:<\/p>\n
1.Vaksin n\u0259dir?<\/strong><\/p>\n Vaksin \u00f6ld\u00fcr\u00fclm\u00fc\u015f v\u0259 ya z\u0259ifl\u0259dilmi\u015f mikroblar v\u0259 onlar\u0131n ifraz etdiyi b\u0259zi antigen xass\u0259li madd\u0259l\u0259rdir. \u0130mmun sistemi bu madd\u0259l\u0259ri antigen kimi q\u0259bul edir v\u0259 ona qar\u015f\u0131 anticisiml\u0259r yarad\u0131r (humoral immunitet). Yaxud da h\u00fcceyr\u0259 immuniteti il\u0259, y\u0259ni T limfositl\u0259r vasit\u0259si il\u0259 m\u0259hv edir. M\u00fcasir d\u00f6vrd\u0259 yoluxucu x\u0259st\u0259likl\u0259r\u0259 qar\u015f\u0131 m\u00fcbariz\u0259 metodlar\u0131ndan \u0259n effektli v\u0259 iqtisad\u0131 c\u0259h\u0259td\u0259n \u0259n \u0259lveri\u015fli \u00fcsul vaksinasiyad\u0131r. \u018fsas prinsipini m\u00fc\u0259yy\u0259n infeksion t\u00f6r\u0259diciy\u0259 qar\u015f\u0131 spesifik immun cavab\u0131n yaranmas\u0131 t\u0259\u015fkil edir.<\/p>\n 2.Vaksinin tarixi<\/strong><\/p>\n \u0130lk peyv\u0259ndin t\u0259xmin\u0259n 1000 il \u00f6nc\u0259 \u00e7inlil\u0259r t\u0259r\u0259find\u0259n tap\u0131ld\u0131\u011f\u0131 haqq\u0131nda f\u0259rziyy\u0259l\u0259r var. \u00c7i\u00e7\u0259k x\u0259st\u0259liyi \u0259leyhin\u0259 ilk peyv\u0259ndin \u00c7inli bir d\u00f6vl\u0259t adam\u0131n\u0131n o\u011fluna vuruldu\u011fu deyilir. \u00c7inlil\u0259rin, \u00e7i\u00e7\u0259k x\u0259st\u0259liyin\u0259 tutulmu\u015f bir x\u0259st\u0259d\u0259ki \u00e7i\u00e7\u0259k yaras\u0131n\u0131n \u00fcst qat\u0131n\u0131 (qab\u0131\u011f\u0131n\u0131) \u0259z\u0259r\u0259k \u0259ld\u0259 etdikl\u0259ri tozu u\u015fa\u011f\u0131n burnuna \u00fcf\u00fcrd\u00fckl\u0259ri z\u0259nn edilir. B\u0259zi tibb tarix\u00e7il\u0259ri is\u0259 u\u015fa\u011f\u0131n qoluna b\u0131\u00e7aqla c\u0131z\u0131q a\u00e7\u0131l\u0131b yaradan \u0259ld\u0259 edil\u0259n qab\u0131\u011f\u0131n c\u0131z\u0131\u011f\u0131n \u00fcz\u0259rin\u0259 ba\u011flanaraq peyv\u0259nd edildiyin\u0259 inan\u0131rlar. Bu g\u00fcn\u00fcm\u00fczd\u0259n 1000 il \u00f6nc\u0259 tap\u0131lan peyv\u0259ndin \u00c7ind\u0259n Orta Asiya \u00f6lk\u0259l\u0259rin\u0259 v\u0259 b\u00fct\u00fcn d\u00fcnyaya yay\u0131ld\u0131\u011f\u0131 deyilir.<\/p>\n 3.Vaksinasiyan\u0131n ba\u015fl\u0131ca u\u011furlar\u0131 hans\u0131lard\u0131r?<\/strong><\/p>\n Son y\u00fcz ild\u0259 peyv\u0259ndl\u0259r bir \u00e7ox x\u0259st\u0259liyin z\u0259r\u0259rl\u0259rini azaltma\u011fa k\u00f6m\u0259k edib. 4.M\u00f6vcud v\u0259ziyy\u0259td\u0259 d\u00fcnyada istifad\u0259 olunan vaksinl\u0259rin m\u00fcqayis\u0259si<\/strong><\/p>\n Firma m\u0259n\u015f\u0259yi : Peyv\u0259ndl\u0259rin istehsal texnologiyalar\u0131:<\/strong><\/p>\n \u2022 Biotech\/Phizer peyv\u0259ndi – RNT \u0259sasl\u0131 \u018fn\u0259n\u0259vi peyv\u0259nd:\u00a0\u018fn\u0259n\u0259vi peyv\u0259ndl\u0259rd\u0259 infeksiyaya s\u0259b\u0259b olan viruslar z\u0259ifl\u0259dil\u0259r\u0259k v\u0259 ya z\u0259r\u0259rsizl\u0259\u015fdiril\u0259r\u0259k insan b\u0259d\u0259nin\u0259 inyeksiya \u00fcsulu il\u0259 b\u0259d\u0259n\u0259 yeridilir. Bel\u0259likl\u0259 insan b\u0259d\u0259ni ona z\u0259r\u0259r verm\u0259y\u0259c\u0259k hala g\u0259tiril\u0259n virusun \u00fcz\u0259rind\u0259 ona qar\u015f\u0131 immunitet qazanma\u011f\u0131 \u00f6yr\u0259nir.<\/p>\n mRNT \u0259sasl\u0131 peyv\u0259nd:\u00a0mRNT \u0259sasl\u0131 peyv\u0259ndl\u0259rd\u0259 is\u0259 virus yerin\u0259 onun genetik kodlar\u0131n\u0131 da\u015f\u0131yan RNT z\u0259ncirind\u0259n \u0259sas bir qisim insan b\u0259d\u0259nin\u0259 inyeksiya \u00fcsulu il\u0259 yeridilir.<\/p>\n Canl\u0131 adenovirus vektorlu peyv\u0259ndl\u0259r:\u00a0Viral vektor peyv\u0259ndl\u0259rd\u0259 d\u0259 genetik texnologiyadan istifad\u0259 edil\u0259r\u0259k virusun da\u015f\u0131d\u0131\u011f\u0131 genetik material\u0131n bir qismi ba\u015fqa virusun i\u00e7in\u0259 yerl\u0259\u015fdirilir v\u0259 insan b\u0259d\u0259nin\u0259 inyeksiya \u00fcsulu il\u0259 yeridilir.<\/p>\n Peyv\u0259ndl\u0259rin istehsal m\u0259nb\u0259l\u0259ri:<\/strong><\/p>\n 1.Biotech\/Phizer peyv\u0259ndi\u00a0– Sintetik kod (Peyv\u0259nd insan qoluna inyeksiya edildiyind\u0259 \u0259z\u0259l\u0259 h\u00fcceyr\u0259l\u0259ri virusu emal etm\u0259y\u0259 ba\u015flay\u0131r); A\u00e7\u0131qlanan immunizasiya faizl\u0259ri:<\/strong><\/p>\n \u2022 Biotech\/Phizer peyv\u0259ndi \u2013 94-96 % Saxlama \u015f\u0259rtl\u0259ri:<\/strong><\/p>\n \u2022 Biotech\/Phizer peyv\u0259ndi – 70 (6 ay) \/ 4 (1 h\u0259ft\u0259) 5.Niy\u0259 m\u0259hz \u00c7in peyv\u0259ndi?<\/strong><\/p>\n \u00c7in istehsal\u0131, Alman peyv\u0259ndi, Amerika peyv\u0259ndi…. Peyv\u0259ndl\u0259rin istehsal olundu\u011fu \u00f6lk\u0259 il\u0259 klassifikasiya olunmas\u0131 do\u011fru deyil. Diqq\u0259t yetirm\u0259li oldu\u011fumuz m\u0259qam, peyv\u0259ndin hans\u0131 \u00fcsulla istehsal edilm\u0259sidir. Peyv\u0259ndin istehsal \u00fcsulu t\u0259hl\u00fck\u0259sizlik n\u00f6qteyi-n\u0259z\u0259rd\u0259n \u0259h\u0259miyy\u0259t k\u0259sb edir.<\/p>\n 6.COV\u0130D peyv\u0259ndl\u0259ri ne\u00e7\u0259 metodla istehsal edilir?<\/strong><\/p>\n Haz\u0131rda 3-c\u00fc fazas\u0131 ba\u015fa \u00e7atd\u0131r\u0131lan iki \u00fcsul m\u00f6vcuddur. 1-ci inaktiv virus \u0259sas\u0131nda peyv\u0259ndl\u0259rin istehsal\u0131. 2-ci is\u0259 mRNT \u00fcsulu il\u0259 istehsal edil\u0259n peyv\u0259ndl\u0259rdir.<\/p>\n 7.Hans\u0131 daha t\u0259hl\u00fck\u0259sizdir?<\/strong><\/p>\n 3-c\u00fc klinik faza s\u0131naq m\u0259rh\u0259l\u0259sini ke\u00e7\u0259n b\u00fct\u00fcn vaksinl\u0259r t\u0259hl\u00fck\u0259siz say\u0131l\u0131r.<\/p>\n 8.Synovac t\u0259r\u0259find\u0259n haz\u0131rlanan peyv\u0259ndin istehsal metodu hans\u0131d\u0131r?<\/p>\n \u0130naktiv yolla. Virus toxuma kulturas\u0131nda \u00e7oxald\u0131l\u0131r v\u0259 kimy\u0259vi yolla tam z\u0259r\u0259rsizl\u0259\u015fdirilir, inaktiv hal al\u0131r. Bir s\u00f6zl\u0259 canl\u0131 virus yox, onun \u0259sas\u0131n\u0131 t\u0259\u015fkil ed\u0259n cans\u0131z madd\u0259l\u0259r – antigenl\u0259r insan orqanizmin\u0259 yeridilir. Bu metodla istehsal olundu\u011fu \u00fc\u00e7\u00fcn daha \u00e7ox \u00fcst\u00fcnl\u00fck ver\u0259 bil\u0259c\u0259yimiz peyv\u0259nddir. \u0130stehsal oldu\u011fu \u00f6lk\u0259y\u0259 deyil, istehsal metoduna diqq\u0259t yetirm\u0259k vacibdir.<\/p>\n 9.D\u00fcnyan\u0131n dig\u0259r \u00f6lk\u0259l\u0259ri v\u0259 \u015firk\u0259tl\u0259ri hans\u0131 s\u0259b\u0259bd\u0259n bu metoda y\u00f6n\u0259lm\u0259di?<\/strong><\/p>\n Bu \u00fcsulla peyv\u0259ndl\u0259rin istehsal prosesi \u00e7ox \u00e7\u0259tin v\u0259 bahal\u0131d\u0131r. T\u0259bii yolla \u00e7oxalan virusdan haz\u0131rlan\u0131r, bu da kifay\u0259t q\u0259d\u0259r t\u0259cr\u00fcb\u0259 v\u0259 investisiya t\u0259l\u0259b edir. \u0130naktiv peyv\u0259ndl\u0259r, asan istehsal edil\u0259 bil\u0259c\u0259k peyv\u0259ndl\u0259r\u0259 aid deyil. Maliyy\u0259 x\u0259rcl\u0259ri y\u00fcks\u0259kdir. N\u0259z\u0259r\u0259 almal\u0131y\u0131q ki, vaksin b\u0259\u015f\u0259riyy\u0259t\u0259 k\u00fclli miqdarda laz\u0131md\u0131r. \u0130naktiv vaksinl\u0259rin q\u0131sa m\u00fcdd\u0259td\u0259 bu miqdarda haz\u0131rlanmas\u0131 is\u0259 \u00e7ox \u00e7\u0259tindir. Bu s\u0259b\u0259bd\u0259n dig\u0259r \u00f6lk\u0259l\u0259r alternativ v\u0259 s\u00fcr\u0259tli istehsala imkan ver\u0259n \u00fcsula daha \u00e7ox \u00fcst\u00fcnl\u00fck verdi. Bundan \u0259lav\u0259, Synovac \u015firk\u0259ti SARS x\u0259st\u0259liyi zaman\u0131 bu metodu inki\u015faf etdirmi\u015fdi, sonradan h\u0259min virus mutasiyaya u\u011frad\u0131\u011f\u0131 \u00fc\u00e7\u00fcn h\u0259min platforma SARS CoV-2 virusuna t\u0259tbiq edildi, m\u0259hz bu s\u0259b\u0259bd\u0259n s\u00fcr\u0259tli n\u0259tic\u0259l\u0259r \u0259ld\u0259 edilmi\u015fdir.<\/p>\n \u018flav\u0259 olaraq qeyd ed\u0259k ki, inaktiv vaksin \u00fcz\u0259rind\u0259 \u00e7al\u0131\u015fan dig\u0259r \u00f6lk\u0259 v\u0259 \u015firk\u0259tl\u0259r d\u0259 t\u0259dqiqatlar\u0131n\u0131 s\u00fcr\u0259tl\u0259 davam etdirir. Bunlardan biri d\u0259 el\u0259 T\u00fcrkiy\u0259d\u0259 haz\u0131rlan\u0131r v\u0259 u\u011furlu n\u0259tic\u0259l\u0259r vermi\u015fdir. T\u0259dqiqatlar\u0131n g\u0259l\u0259n ilin may ay\u0131nad\u0259k yekunla\u015fmas\u0131 g\u00f6zl\u0259nilir.<\/p>\n 10.\u00c7ind\u0259 istehsal olunan Synovac peyv\u0259ndi t\u0259sdiq olunubmu v\u0259 onun \u201d3-c\u00fc faza\u201d n\u0259tic\u0259l\u0259ri a\u00e7\u0131qlanmadan istifad\u0259si m\u00fcmk\u00fcnd\u00fcrm\u00fc?<\/strong><\/p>\n Sinovac peyv\u0259ndi \u201c3-c\u00fc faza\u201d s\u0131naq m\u0259rh\u0259l\u0259sin\u0259 \u0259n erk\u0259n ba\u015flayan peyv\u0259nddir. Bununla ba\u011fl\u0131 bu s\u0131naq m\u0259rh\u0259l\u0259sind\u0259 geni\u015f ictimaiyy\u0259t\u0259 t\u0259tbiq edilm\u0259l\u0259r h\u0259yata ke\u00e7irilib. Art\u0131q Braziliya, \u00c7ili, \u0130ndoneziya, eyni zamanda T\u00fcrkiy\u0259 peyv\u0259ndin s\u0131naqlar\u0131n\u0131n u\u011furlu oldu\u011funu t\u0259sdiq edib. Ara\u015fd\u0131rmalar zaman\u0131 peyv\u0259ndl\u0259rin t\u0259hl\u00fck\u0259sizlik n\u00f6qteyi-n\u0259z\u0259rd\u0259n m\u00fcsb\u0259t n\u0259tic\u0259l\u0259r verm\u0259si vacibdir. Bu n\u0259tic\u0259l\u0259r olmadan peyv\u0259ndin istifad\u0259si m\u00fcmk\u00fcns\u00fcz say\u0131l\u0131r.<\/p>\n 11.Peyv\u0259ndl\u0259m\u0259 m\u0259cburi olacaqm\u0131?<\/strong><\/p>\n Koronavirusa qar\u015f\u0131 peyv\u0259ndl\u0259m\u0259 k\u00f6n\u00fcll\u00fc olacaq.<\/p>\n 12.Synovac vaksininin qiym\u0259ti ne\u00e7\u0259y\u0259dir? Vaksinl\u0259r hans\u0131 m\u0259nb\u0259 hesab\u0131na al\u0131nacaq?<\/strong><\/p>\n \u0130stahsal\u00e7\u0131 \u015firk\u0259t t\u0259r\u0259find\u0259n \u00f6lk\u0259l\u0259r\u0259 vaksinin sat\u0131lma qiym\u0259tinin konfidensial saxlanmas\u0131 \u015f\u0259rti ikit\u0259r\u0259fli m\u00fcqavil\u0259d\u0259 \u00f6z \u0259ksini tapm\u0131\u015fd\u0131r. Yaln\u0131z bunu qeyd ed\u0259 bil\u0259rik ki, Az\u0259rbaycan v\u0259 T\u00fcrkiy\u0259 vaksinl\u0259ri eyni qiym\u0259t\u0259 \u0259ld\u0259 edib. Vaksinl\u0259r Koronavirusla M\u00fcbariz\u0259 Fonduna toplanm\u0131\u015f v\u0259saitl\u0259r hesab\u0131na al\u0131nacaqd\u0131r.<\/p>\n 13.Peyv\u0259nd vurulark\u0259n qeydiyyat, yoxsa ya\u015fay\u0131\u015f yeri n\u0259z\u0259r\u0259 al\u0131nacaq?<\/strong><\/p>\n Peyv\u0259nd olunmaq ist\u0259y\u0259n v\u0259t\u0259nda\u015flar\u0131n istifad\u0259sind\u0259 elektron q\u0259bula yaz\u0131lmaq \u00fc\u00e7\u00fcn (randevu) sistemi olacaq. Bu sistem vasit\u0259sil\u0259 onlar peyv\u0259nd olunmaq \u00fc\u00e7\u00fcn ya\u015fay\u0131\u015f yerl\u0259rin\u0259 \u0259n yax\u0131n tibb m\u0259nt\u0259q\u0259sini v\u0259 uy\u011fun saat\u0131 se\u00e7m\u0259k imkan\u0131 \u0259ld\u0259 ed\u0259c\u0259kl\u0259r.<\/p>\n 14.\u0130lkin m\u0259rh\u0259l\u0259d\u0259 kiml\u0259rin peyv\u0259ndl\u0259nm\u0259si n\u0259z\u0259rd\u0259 tutulub?<\/strong><\/p>\n COV\u0130D-19 x\u0259st\u0259liyi \u0259leyhin\u0259 vaksinasiya il\u0259 \u0259hat\u0259 olunan y\u00fcks\u0259k riskli \u0259hali qruplar\u0131 a\u015fa\u011f\u0131dak\u0131lard\u0131r:<\/p>\n 1-ci m\u0259rh\u0259l\u0259 – S\u0259hiyy\u0259 i\u015f\u00e7il\u0259ri; 15.Vaksin preparatlar\u0131n\u0131n se\u00e7imind\u0259 hans\u0131 meyarlar \u0259sas g\u00f6t\u00fcr\u00fcl\u00fcr?<\/strong><\/p>\n \u2022 vaksin preparatlar\u0131n\u0131n t\u0259hl\u00fck\u0259sizliyi (vaksinasiyadan sonra ba\u015f ver\u0259 bil\u0259c\u0259k m\u00fcmk\u00fcn reaksiya v\u0259 a\u011f\u0131rla\u015fmalar\u0131n say\u0131 minimum olanlar); 16.Vaksinl\u0259rin idxal\u0131 zaman\u0131 da\u015f\u0131nmas\u0131, saxlanmas\u0131, istifad\u0259sin\u0259 dair t\u0259hl\u00fck\u0259sizlik qaydalar\u0131na nec\u0259 riay\u0259t olunacaq?<\/strong><\/p>\n Vaksinasiyan\u0131n t\u0259tbiq edilm\u0259si \u00fc\u00e7\u00fcn t\u0259l\u0259b olunan texniki \u015f\u0259rtl\u0259r\u0259 m\u00fctl\u0259q riay\u0259t olunacaq. 17.Az\u0259rbaycan v\u0259t\u0259nda\u015f\u0131n\u0131n xarici \u00f6lk\u0259y\u0259 s\u0259f\u0259ri zaman\u0131 ehtiyac yaranarsa, peyv\u0259ndl\u0259nm\u0259sin\u0259 dair t\u0259sdiqedici h\u0259r hans\u0131 s\u0259n\u0259d veril\u0259c\u0259kmi?<\/strong><\/p>\n Peyv\u0259nd olunmu\u015f \u015f\u0259xsl\u0259rin cari qeydiyyat\u0131 elektron qaydada apar\u0131lacaq. Z\u0259rur\u0259t yarand\u0131\u011f\u0131 halda, xarici \u00f6lk\u0259l\u0259r\u0259 s\u0259f\u0259r zaman\u0131 v\u0259 ya dig\u0259r s\u0259b\u0259bl\u0259rd\u0259n v\u0259t\u0259nda\u015f m\u00fcraci\u0259t ed\u0259rs\u0259, t\u0259sdiqedici s\u0259n\u0259d t\u0259qdim olunacaq.<\/p>\n 18.Vaksinasiyadan imtina olarsa, ona m\u00fcnasib\u0259t nec\u0259 olacaq?<\/strong><\/p>\n Vaksinasiya k\u00f6n\u00fcll\u00fcl\u00fck prinsipin\u0259 \u0259sasland\u0131\u011f\u0131 \u00fc\u00e7\u00fcn h\u0259r hans\u0131 inzibati t\u0259dbirin h\u0259yata ke\u00e7irilm\u0259si n\u0259z\u0259rd\u0259 tutulmam\u0131\u015fd\u0131r.<\/p>\n 19.Vaksind\u0259n sonra \u00f6l\u00fcm hallar\u0131n\u0131n olmas\u0131 qeyd\u0259 al\u0131na bil\u0259rmi?<\/strong><\/p>\n Vaksind\u0259n sonra g\u00f6zl\u0259diyimiz \u0259n ciddi reaksiya allergiya v\u0259 anafilaktik \u015fok ola bil\u0259r. Bu hallar b\u00fct\u00fcn peyv\u0259ndl\u0259rd\u0259n, h\u0259tta antibiotikl\u0259rd\u0259n sonra da m\u00fc\u015fahid\u0259 edil\u0259 bil\u0259r. Vaksind\u0259n bir ne\u00e7\u0259 g\u00fcn sonra ba\u015f ver\u0259n b\u00fct\u00fcn \u00f6l\u00fcm hallar\u0131n\u0131 vaksinl\u0259 \u0259laq\u0259l\u0259ndirm\u0259k do\u011fru deyil. S\u0259b\u0259bl\u0259r ciddi \u015f\u0259kild\u0259 ara\u015fd\u0131r\u0131lmal\u0131d\u0131r. \u0130ndiy\u0259 q\u0259d\u0259r Sinovac vaksininin 3-c\u00fc klinik faza t\u0259dqiqatlar\u0131 zaman\u0131 \u00f6l\u00fcm hal\u0131 m\u00fc\u015fahid\u0259 olunmam\u0131\u015fd\u0131r.<\/p>\n 20.Koronavirusa yoluxan \u015f\u0259xsl\u0259r d\u0259 peyv\u0259nd olunacaqm\u0131?<\/strong><\/p>\n Koronavirusa yoluxmu\u015f \u015f\u0259xsl\u0259r vaksinasiya strategiyas\u0131na uy\u011fun olaraq vaksinasiya il\u0259 \u0259hat\u0259 olunan \u0259n a\u015fa\u011f\u0131 riskli \u0259hali qruplar\u0131na aid edilirl\u0259r. Bu s\u0259b\u0259bd\u0259n bu \u015f\u0259xsl\u0259rin vaksinasiyas\u0131 dig\u0259r riskli \u0259hali qruplar\u0131 il\u0259 m\u00fcqayis\u0259d\u0259 \u0259n sonda apar\u0131lacaq.<\/p>\n 21.Vaksin vurulan zaman \u015f\u0259xsin yan x\u0259st\u0259likl\u0259ri n\u0259z\u0259r\u0259 al\u0131nacaqm\u0131?<\/strong><\/p>\n B\u0259li, \u0259lb\u0259tt\u0259 n\u0259z\u0259r\u0259 al\u0131nacaq. Sinovac vaksinini istehsal ed\u0259n \u015firk\u0259t t\u0259r\u0259find\u0259n yaln\u0131z vaksinin elementl\u0259rin\u0259 qar\u015f\u0131 h\u0259ssasl\u0131\u011f\u0131 olan, vaksin vurulan zaman y\u00fcks\u0259k b\u0259d\u0259n h\u0259rar\u0259ti v\u0259 ya xroniki x\u0259st\u0259liyinin k\u0259skinl\u0259\u015fm\u0259si m\u0259rh\u0259l\u0259sind\u0259 olan insanlara vurulmas\u0131 t\u00f6vsiy\u0259 edilmir.<\/p>\n 22.\u018fg\u0259r peyv\u0259nd olunsam, virusa yenid\u0259n yoluxa v\u0259 ba\u015fqalar\u0131n\u0131 da yoluxdura bil\u0259r\u0259mmi? Peyv\u0259nd virusdan tam qoruyurmu?<\/strong><\/p>\n Peyv\u0259ndin ikinci dozas\u0131 vurulduqdan 2 h\u0259ft\u0259 sonra peyv\u0259nd \u00f6z t\u0259sirini g\u00f6st\u0259rm\u0259y\u0259 ba\u015flay\u0131r v\u0259 qanda anticisml\u0259ri t\u0259yin etm\u0259k m\u00fcmk\u00fcn olur. (bu fakt h\u0259r k\u0259sin immun sistemin\u0259 g\u00f6r\u0259 d\u0259yi\u015f\u0259 bil\u0259r). M\u00fcxt\u0259lif peyv\u0259ndl\u0259r \u00fcz\u0259rind\u0259 apar\u0131lan t\u0259dqiqatlar\u0131n n\u0259tic\u0259l\u0259ri f\u0259rqlidir. T\u00fcrkiy\u0259d\u0259 apar\u0131lan t\u0259dqiqatlar Sinovac vaksininin effektivlik d\u0259r\u0259c\u0259sini 92 faiz qiym\u0259tl\u0259ndirir.<\/p>\n 23.Peyv\u0259nd olunandan sonra da maska taxma\u011fa, sosial m\u0259saf\u0259 saxlama\u011fa ehtiyac varm\u0131?<\/strong><\/p>\n Peyv\u0259ndin t\u0259sirinin ikinci dozan\u0131n vurulmas\u0131ndan t\u0259xmin\u0259n 2 h\u0259ft\u0259 sonra ba\u015flamas\u0131n\u0131 n\u0259z\u0259r\u0259 alaraq maska taxma\u011fa, \u0259l gigiyenas\u0131na v\u0259 fiziki m\u0259saf\u0259y\u0259 riay\u0259t etm\u0259y\u0259 m\u00fctl\u0259q \u0259m\u0259l etm\u0259liyik. \u00c7\u00fcnki h\u0259min m\u00fcdd\u0259td\u0259 yuxar\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131nda virusu da\u015f\u0131ya bil\u0259rik. Vaksin olunan \u015f\u0259xs \u00fc\u00e7\u00fcn bu hal he\u00e7 bir t\u0259hl\u00fck\u0259 yaratmasa da, \u0259traf\u0131m\u0131zda olan v\u0259 risk qrupuna aid olan insanlar \u00fc\u00e7\u00fcn t\u0259hl\u00fck\u0259 m\u0259nb\u0259yi ola bil\u0259rik.<\/p>\n Eyni zamanda n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r ki, maskan\u0131n tax\u0131lmas\u0131, sosial m\u0259saf\u0259nin g\u00f6zl\u0259nilm\u0259si kimi m\u0259s\u0259l\u0259l\u0259r Nazirl\u0259r Kabineti yan\u0131nda Operativ Q\u0259rargah\u0131n q\u0259rarlar\u0131 il\u0259 t\u0259nziml\u0259nir v\u0259 ist\u0259nil\u0259n halda bu qaydalara riay\u0259t olunmal\u0131d\u0131r.<\/p>\n 24.\u00dcmumiyy\u0259tl\u0259 indiy\u0259d\u0259k test olunmayan, amma vaksin vurulmal\u0131 olan \u015f\u0259xsl\u0259r \u0259vv\u0259lc\u0259 koronavirus ke\u00e7irib-ke\u00e7irm\u0259dikl\u0259rin\u0259 g\u00f6r\u0259 test olunacaqlarm\u0131?<\/strong><\/p>\n Vaksin istehsal\u00e7\u0131lar\u0131 t\u0259r\u0259find\u0259n vaksinl\u0259rin istifad\u0259sin\u0259 dair t\u0259limatda vaksin \u00f6nc\u0259si testin apar\u0131lmas\u0131 kimi t\u0259l\u0259b qoyulmur. D\u00fcnya \u00f6lk\u0259l\u0259rinin t\u0259cr\u00fcb\u0259sin\u0259 g\u00f6r\u0259 vaksinasiya prosesinin effektivliyi \u00fc\u00e7\u00fcn q\u0131sa m\u00fcdd\u0259td\u0259 m\u00fcmk\u00fcn q\u0259d\u0259r \u00e7ox insan\u0131n peyv\u0259nd olunmas\u0131 m\u00fctl\u0259qdir. Bu bax\u0131mdan \u0259lav\u0259 testl\u0259rin apar\u0131lmas\u0131n\u0131n vaxt itkisi olmas\u0131n\u0131, assimptomatik \u015f\u0259xsl\u0259rd\u0259 b\u0259z\u0259n testl\u0259r apar\u0131lsa bel\u0259 virusun a\u015fkarlanmamas\u0131n\u0131 n\u0259z\u0259r\u0259 alaraq \u0259lav\u0259 m\u00fcayin\u0259l\u0259rin apar\u0131lmas\u0131 n\u0259z\u0259rd\u0259 tutulmam\u0131\u015fd\u0131r (tibbi ara\u015fd\u0131rmalar g\u00f6st\u0259rir ki, assimptomatik x\u0259st\u0259l\u0259rd\u0259 ya immun cavab yaranm\u0131r, ya da \u00e7ox z\u0259if yaran\u0131r). X\u00fcsusil\u0259 qeyd etm\u0259liyik ki, COVID-19 virusuna yoluxmu\u015f v\u0259 sa\u011falm\u0131\u015f insanlar\u0131n peyv\u0259nd olunmas\u0131nda da he\u00e7 bir \u0259ks g\u00f6st\u0259ri\u015f yoxdur.<\/p>\n 25.Vaksinasiya zaman\u0131 b\u0259d\u0259nd\u0259 h\u0259r hans\u0131 f\u0259sad yaranarsa, v\u0259t\u0259nda\u015flar i\u015f qabiliyy\u0259tini itir\u0259rs\u0259, bunun \u00fc\u00e7\u00fcn h\u0259r hans\u0131 kompensasiya n\u0259z\u0259rd\u0259 tutulubmu?<\/strong><\/p>\n \u201cYoluxucu x\u0259st\u0259likl\u0259rin immunoprofilaktikas\u0131 haqq\u0131nda\u201d Az\u0259rbaycan Respublikas\u0131n\u0131n Qanununun 15-ci madd\u0259sin\u0259 \u0259sas\u0259n \u0259m\u0259k qabiliyy\u0259tinin m\u00fcv\u0259qq\u0259ti itirilm\u0259si postvaksinal f\u0259sadla \u0259laq\u0259dar olduqda v\u0259t\u0259nda\u015f, fasil\u0259siz i\u015f staj\u0131ndan as\u0131l\u0131 olmayaraq, ald\u0131\u011f\u0131 orta \u0259m\u0259k haqq\u0131n\u0131n 100 faizi miqdar\u0131nda m\u00fcavin\u0259t almaq h\u00fcququna malikdir. Yetkinlik ya\u015f\u0131na \u00e7atmayan \u015f\u0259xs postvaksinal f\u0259sadla \u0259laq\u0259dar x\u0259st\u0259liy\u0259 tutulduqda ona qanunvericilikd\u0259 m\u00fc\u0259yy\u0259n edil\u0259n qaydada sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu m\u00fc\u0259yy\u0259n edil\u0259n\u0259d\u0259k onun valideynl\u0259rind\u0259n biri v\u0259 ya qanuni n\u00fcmay\u0259nd\u0259si, fasil\u0259siz i\u015f staj\u0131ndan as\u0131l\u0131 olmayaraq, orta \u0259m\u0259k haqq\u0131n\u0131n 100 faizi miqdar\u0131nda m\u00fcavin\u0259t almaq h\u00fcququna malikdir. 26.\u018fhalinin n\u0259 q\u0259d\u0259r hiss\u0259sin\u0259 peyv\u0259nd vurulmal\u0131d\u0131r ki, t\u0259hl\u00fck\u0259 tamamil\u0259 bitmi\u015f hesab olunsun?<\/strong><\/p>\n \u00d6lk\u0259nin v\u0259 d\u00fcnyan\u0131n pandemiya il\u0259 m\u00fcbariz\u0259d\u0259 u\u011fur qazana bilm\u0259si \u00fc\u00e7\u00fcn \u0259halinin t\u0259xmin\u0259n 60 %-d\u0259 virusa qar\u015f\u0131 immunitet (k\u00fctl\u0259vi immunitet) formala\u015fmal\u0131d\u0131r. Bu g\u00f6st\u0259ricinin bir hiss\u0259si art\u0131q yoluxub sa\u011falm\u0131\u015f \u015f\u0259xsl\u0259rin, dig\u0259r hiss\u0259si is\u0259 peyv\u0259nd olunmu\u015f \u015f\u0259xsl\u0259rin hesab\u0131na formala\u015f\u0131r (M\u0259nb\u0259: Vaksinasiya strategiyas\u0131).<\/p>\n 27.Koronavirusa yoluxan v\u0259 sa\u011falan, m\u00fcalic\u0259 m\u00fcdd\u0259tini evind\u0259 ke\u00e7ir\u0259n, lakin he\u00e7 bir yerd\u0259 qeydiyyata d\u00fc\u015fm\u0259y\u0259n (poliklinika v\u0259 x\u0259st\u0259xana) \u015f\u0259xsl\u0259r d\u0259 vaksinasiya olunacaqm\u0131?<\/strong><\/p>\n Vaksinasiya prosesi k\u00f6n\u00fcll\u00fc oldu\u011fu \u00fc\u00e7\u00fcn s\u00f6z\u00fcged\u0259n \u015f\u0259xsl\u0259r d\u0259 peyv\u0259nd oluna bil\u0259r. Bu \u015f\u0259xsl\u0259rin peyv\u0259ndl\u0259m\u0259si vaksinasiya strategiyas\u0131na uy\u011fun apar\u0131lacaq.<\/p>\n 28.Vaksin m\u00fcmk\u00fcn yan t\u0259sirl\u0259ri hans\u0131lard\u0131r? Hans\u0131 \u0259ks g\u00f6st\u0259ri\u015fl\u0259r ola bil\u0259r?<\/strong><\/p>\n \u018fhali aras\u0131nda yay\u0131lan, vaksind\u0259n sonra m\u00fcmk\u00fcn ola bil\u0259c\u0259k – ba\u015f a\u011fr\u0131s\u0131, \u0259z\u0259l\u0259 a\u011fr\u0131s\u0131, q\u0131zd\u0131rma v\u0259 s. kimi \u0259lam\u0259tl\u0259r \u0259ks g\u00f6st\u0259ri\u015f deyil, \u0259ksin\u0259 g\u00f6zl\u0259nil\u0259n n\u0259tic\u0259dir v\u0259 tibbi c\u0259h\u0259td\u0259n b\u0259d\u0259nin vaksin\u0259 m\u00fcsb\u0259t reaksiya verm\u0259sinin g\u00f6st\u0259ricisidir.<\/p>\n Vaksin istehsal ed\u0259n \u015firk\u0259t t\u0259r\u0259find\u0259n yaln\u0131z vaksinin elementl\u0259rin\u0259 qar\u015f\u0131 h\u0259ssasl\u0131\u011f\u0131 olan, vaksin vurulan zaman y\u00fcks\u0259k b\u0259d\u0259n h\u0259rar\u0259ti v\u0259 ya xroniki x\u0259st\u0259liyinin k\u0259skinl\u0259\u015fm\u0259si m\u0259rh\u0259l\u0259sind\u0259 olan insanlara vurulmas\u0131 t\u00f6vsiy\u0259 edilmir (M\u0259nb\u0259: Vaksinin istifad\u0259 t\u0259limat\u0131) \u2013 T\u018fB\u0130B<\/p>\n 29.Az\u0259rbaycandan ba\u015fqa hans\u0131 d\u00f6vl\u0259tl\u0259r bu peyv\u0259ndi almaq niyy\u0259tind\u0259dir v\u0259 ya art\u0131q alm\u0131\u015fd\u0131r?<\/strong><\/p>\n \u00c7in, \u0130ndoneziya, T\u00fcrkiy\u0259, Braziliya v\u0259 s.<\/p>\n 30.S\u00f6z\u00fcged\u0259n vaksinl\u0259 ba\u011fl\u0131 d\u00fcnyada s\u0131naq m\u0259rh\u0259l\u0259l\u0259rin\u0259 n\u0259 zamandan ba\u015flan\u0131l\u0131b? Az\u0259rbaycan da \u0259ld\u0259 etdiyi vaksini laborator s\u0131naqlardan ke\u00e7iribmi? V\u0259 hans\u0131 n\u0259tic\u0259l\u0259r \u0259ld\u0259 olunub?<\/strong><\/p>\n Bu vaksinl\u0259 ba\u011fl\u0131 t\u0259dqiqatlara d\u00fcnya \u00f6lk\u0259l\u0259ri yeni n\u00f6v koronavirus infeksiyas\u0131 pandemiya elan olundu\u011fu g\u00fcnd\u0259n etibar\u0259n ba\u015flay\u0131blar. Bu bar\u0259d\u0259 m\u0259tbuatda m\u0259lumatlar geni\u015f yay\u0131lm\u0131\u015fd\u0131r. Art\u0131q s\u0131naqlar\u0131n h\u0259yata ke\u00e7irildiyi \u00c7in, \u0130ndoneziya, Braziliya, T\u00fcrkiy\u0259 v\u0259 s. \u00f6lk\u0259l\u0259r m\u00fcsb\u0259t n\u0259tic\u0259l\u0259r \u0259ld\u0259 etmi\u015fdir. Az\u0259rbaycana g\u0259l\u0259n h\u0259r bir vaksin seriyas\u0131 m\u00fcvafiq laboratoriyalar\u0131nda yoxlan\u0131ld\u0131qdan v\u0259 t\u0259hl\u00fck\u0259sizliyi tam t\u0259sdiq olunduqdan sonra \u00f6lk\u0259mizd\u0259 t\u0259tbiq olunacaq.<\/p>\n 31.Vaksinin effektivliyini n\u0259 q\u0259d\u0259rdir? \u0130nsanda yaratd\u0131\u011f\u0131 immunetit n\u0259 q\u0259d\u0259r davam edir?<\/strong><\/p>\n Apar\u0131lan t\u0259dqiqatlar\u0131n n\u0259tic\u0259sin\u0259 g\u00f6r\u0259 vaksinin effektivliyi 92 %-dir. \u0130nsanda yaratd\u0131\u011f\u0131 immunitetin m\u00fcdd\u0259ti minimum 6 ay -1 ildir, maksimum m\u00fcdd\u0259t is\u0259 h\u0259l\u0259 r\u0259smi t\u0259sdiql\u0259nm\u0259mi\u015fdir.<\/p>\n 32.\u018fg\u0259r bir insan\u0131n peyv\u0259ndl\u0259nm\u0259si \u00fc\u00e7\u00fcn 2 doza t\u0259l\u0259b olunursa, bu dozalar aras\u0131 ne\u00e7\u0259 g\u00fcn minimal v\u0259 maksimal m\u00fcdd\u0259t t\u0259l\u0259b olunur?<\/strong><\/p>\n \u0130stehsal\u00e7\u0131 \u015firk\u0259tin t\u00f6vsiy\u0259sin\u0259 \u0259sas\u0259n dozalararas\u0131 m\u00fcdd\u0259t 21 g\u00fcn m\u00fc\u0259yy\u0259nl\u0259\u015fdirilmi\u015fdir.<\/p>\n 33.\u00dcST-\u00fcn bu vaksinl\u0259r\u0259 r\u0259smi m\u00fcnasib\u0259ti nec\u0259dir? Qurum bu vaksinl\u0259rin istifad\u0259sini t\u00f6vsiy\u0259 edirmi?<\/strong><\/p>\n \u00dcST-\u00fcn bu vaksini t\u0259sdiq etm\u0259si \u00fc\u00e7\u00fcn istehsal\u00e7\u0131 t\u0259r\u0259find\u0259n b\u00fct\u00fcn s\u0259n\u0259dl\u0259r art\u0131q t\u0259qdim olunmu\u015fdur. N\u0259tic\u0259l\u0259rin yax\u0131n g\u0259l\u0259c\u0259kd\u0259 a\u00e7\u0131qlanmas\u0131 g\u00f6zl\u0259nilir. H\u0259m\u00e7inin d\u00fcnya t\u0259cr\u00fcb\u0259sind\u0259 AB\u015e, \u0130ngilt\u0259r\u0259, Rusiya, T\u00fcrkiy\u0259 v\u0259 s. \u00f6lk\u0259l\u0259r \u00dcST-\u00fcn t\u00f6vsiy\u0259si olmadan da, m\u00fcxt\u0259lif vaksinl\u0259rin \u00f6z \u00f6lk\u0259l\u0259rind\u0259 t\u0259cili istifad\u0259sin\u0259 icaz\u0259 vermi\u015fdir.<\/p>\n 34.Vaksinasiya yaln\u0131z d\u00f6vl\u0259t x\u0259st\u0259xanalar\u0131nda t\u0259tbiq olunacaq yoxsa \u00f6d\u0259ni\u015fli \u0259saslarla \u00f6z\u0259l tibb m\u00fc\u0259ssis\u0259l\u0259ri d\u0259 bu proses\u0259 c\u0259lb olunacaq?<\/strong><\/p>\n Hal-haz\u0131rda ilkin m\u0259rh\u0259l\u0259d\u0259 yaln\u0131z d\u00f6vl\u0259t x\u0259st\u0259xanalar\u0131nda vaksinasiya strategiyas\u0131nda n\u0259z\u0259rd\u0259 tutulan \u0259hali qruplar\u0131 \u00fc\u00e7\u00fcn istifad\u0259si n\u0259z\u0259rd\u0259 tutulub, g\u0259l\u0259c\u0259kd\u0259 vaksinl\u0259rin say\u0131 v\u0259 m\u00fcxt\u0259lifliyi artd\u0131qca dig\u0259r \u00f6z\u0259l tibb m\u00fc\u0259ssis\u0259l\u0259rinin d\u0259 proses\u0259 qo\u015fulmas\u0131na bax\u0131la bil\u0259r.<\/p>\n 35.Vaksinin t\u0259tbiqi zaman\u0131 \u00f6lk\u0259mizd\u0259 ya\u015fayan xarici v\u0259t\u0259nda\u015flar da n\u0259z\u0259r\u0259 al\u0131n\u0131bm\u0131?<\/strong><\/p>\n \u0130lkin m\u0259rh\u0259l\u0259d\u0259 yaln\u0131z \u00f6lk\u0259 v\u0259t\u0259nda\u015flar\u0131n\u0131n vaksin edilm\u0259si n\u0259z\u0259rd\u0259 tutulub.<\/p>\n 36.Peyv\u0259nd olunark\u0259n hans\u0131 qaydalara riay\u0259t olunmal\u0131d\u0131r? Peyv\u0259ndl\u0259nmi\u015f \u015f\u0259xsl\u0259r n\u0259y\u0259 diqq\u0259t etm\u0259lidir?<\/strong><\/p>\n H\u0259r bir peyv\u0259nd olunan \u015f\u0259xs\u0259 m\u0259lumat v\u0259r\u0259q\u0259sinin t\u0259qdim edilm\u0259si n\u0259z\u0259rd\u0259 tutulmu\u015fdur. Burada v\u0259t\u0259nda\u015flar\u0131m\u0131z peyv\u0259ndin g\u00f6zl\u0259nil\u0259n t\u0259sirl\u0259ri, ikinci dozan\u0131n vurulma vaxt\u0131 v\u0259 s. m\u0259lumatlarla tan\u0131\u015f ola bil\u0259c\u0259kl\u0259r.<\/p>\n 37.Hamil\u0259 qad\u0131nlara v\u0259 k\u00f6rp\u0259l\u0259r\u0259 d\u0259 vaksin vurulacaqm\u0131?<\/strong><\/p>\n \u0130stahsal\u00e7\u0131 \u015firk\u0259tin t\u00f6vsiy\u0259sin\u0259 \u0259sas\u0259n 18 ya\u015fa q\u0259d\u0259r \u0259hali k\u00fctl\u0259sin\u0259, hamil\u0259 v\u0259 s\u00fcdver\u0259n qad\u0131nlara peyv\u0259ndin vurulmas\u0131 t\u00f6vsiy\u0259 edilmir. \u00c7\u00fcnki bu istiqam\u0259td\u0259 h\u0259l\u0259 t\u0259dqiqat apar\u0131lmayib.<\/p>\n 38.K\u00fctl\u0259vi peyv\u0259ndl\u0259m\u0259nin n\u0259tic\u0259l\u0259ri n\u0259 vaxtdan \u00f6z\u00fcn\u00fc g\u00f6st\u0259r\u0259c\u0259k?<\/strong><\/p>\n \u018fhalinin t\u0259xmin\u0259n 60%-i virusa qar\u015f\u0131 vaksinaya prosesin\u0259 qo\u015fulmald\u0131d\u0131r ki, k\u00fctl\u0259vi immunitet formala\u015fs\u0131n. Bu t\u0259qdird\u0259 biz pandemiya il\u0259 m\u00fcbariz\u0259d\u0259 u\u011fur qazanaca\u011f\u0131m\u0131z\u0131 s\u00f6yl\u0259y\u0259 bil\u0259rik. D\u0259qiq tarix dem\u0259k \u00e7\u0259tin olsa da, prosesin 1 il \u0259rzind\u0259 olaca\u011f\u0131 m\u00fct\u0259x\u0259ssisl\u0259rin ilkin r\u0259yidir.<\/p>\n 39.Qrip peyv\u0259ndi v\u0259 ya yax\u0131n zamanlarda dig\u0259r x\u0259st\u0259likl\u0259r\u0259 qar\u015f\u0131 peyv\u0259nd vurdurmu\u015f \u015f\u0259xsl\u0259r d\u0259 bu peyv\u0259ndi vurdura bil\u0259rmi?<\/strong><\/p>\n \u018fg\u0259r vurulmu\u015f peyv\u0259ndd\u0259n 1 ay m\u00fcdd\u0259t ke\u00e7ibs\u0259, n\u00f6vb\u0259ti peyv\u0259ndin vurulmas\u0131 \u00fc\u00e7\u00fcn he\u00e7 bir \u0259ks g\u00f6st\u0259ri\u015f yoxdur.<\/p>\n 40.Az\u0259rbaycanda COVID-19 virusuna qar\u015f\u0131 peyv\u0259ndin vurulmas\u0131 S\u0259hiyy\u0259 Nazirliyi v\u0259 ya T\u018fB\u0130B t\u0259r\u0259find\u0259n apar\u0131lacaq?<\/strong><\/p>\n Az\u0259rbaycan Respublikas\u0131 S\u0259hiyy\u0259 Nazirliyi, \u0130cbari Tibbi S\u0131\u011forta \u00fczr\u0259 D\u00f6vl\u0259t Agentliyi v\u0259 T\u018fB\u0130B-in birg\u0259 s\u0259yl\u0259ri n\u0259tic\u0259sind\u0259 Az\u0259rbaycanda COV\u0130D-19 virusuna qar\u015f\u0131 peyv\u0259ndl\u0259m\u0259 t\u0259dbirl\u0259ri h\u0259yata ke\u00e7iril\u0259c\u0259k.<\/p>\n 41.Tibb i\u015f\u00e7il\u0259ri \u00fc\u00e7\u00fcn peyv\u0259nd m\u0259cburi ola bil\u0259rmi?<\/strong><\/p>\n D\u00fcnyan\u0131n h\u0259r bir yerind\u0259 oldu\u011fu kimi tibb i\u015f\u00e7il\u0259ri yeni n\u00f6v koronavirus infeksiyas\u0131na yoluxma ehtimal\u0131 y\u00fcks\u0259k olan \u0259hali qruplar\u0131na aiddirl\u0259r. G\u00fcnd\u0259lik olaraq onlar \u00e7oxlu sayda insanlarla s\u0131x t\u0259masda olurlar, onlara m\u00fcxt\u0259lif profilli tibbi xidm\u0259tl\u0259r g\u00f6st\u0259rirl\u0259r. Tibb i\u015f\u00e7il\u0259rinin virusa yoluxma riski y\u00fcks\u0259kdir. Onlar\u0131n sa\u011flaml\u0131\u011f\u0131n\u0131n qorunmas\u0131 \u00fc\u00e7\u00fcn tibb i\u015f\u00e7il\u0259rinin vaksinasiya olunmas\u0131 m\u0259qs\u0259d\u0259uy\u011fundur. Tibbi i\u015f\u00e7il\u0259ri aras\u0131nda apar\u0131lm\u0131\u015f daxili sor\u011fular\u0131n n\u0259tic\u0259l\u0259rind\u0259n m\u0259lum olur ki, onlar\u0131n 80%-i vaksin olunmalar\u0131n\u0131 m\u00fcsb\u0259t qarsalay\u0131rlar.<\/p>\n","protected":false},"excerpt":{"rendered":" Tibbi \u018frazi B\u00f6lm\u0259l\u0259rini \u0130dar\u0259etm\u0259 Birliyi (T\u018fB\u0130B) vaksinasiya il\u0259 ba\u011fl\u0131 suallara ayd\u0131nl\u0131q g\u0259tirib. H\u0259min m\u0259s\u0259l\u0259l\u0259ri t\u0259qdim edir: 1.Vaksin n\u0259dir? Vaksin \u00f6ld\u00fcr\u00fclm\u00fc\u015f v\u0259 ya z\u0259ifl\u0259dilmi\u015f mikroblar v\u0259 onlar\u0131n ifraz etdiyi b\u0259zi antigen xass\u0259li madd\u0259l\u0259rdir. \u0130mmun sistemi bu madd\u0259l\u0259ri antigen kimi q\u0259bul edir v\u0259 ona qar\u015f\u0131 anticisiml\u0259r yarad\u0131r (humoral immunitet). Yaxud da h\u00fcceyr\u0259 immuniteti il\u0259, y\u0259ni T limfositl\u0259r […]<\/p>\n","protected":false},"author":2,"featured_media":8241,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-society"],"yoast_head":"\n
\n1960-c\u0131 ill\u0259rd\u0259 q\u0131z\u0131lcaya qar\u015f\u0131 peyv\u0259nd icad olunana q\u0259d\u0259r h\u0259r il bu x\u0259st\u0259likd\u0259n t\u0259xmin\u0259n 2,6 milyon adam \u00f6l\u00fcrd\u00fc.
\n\u00dcST-nin m\u0259lumatlar\u0131na g\u00f6r\u0259, 2000-2017-ci ill\u0259r aral\u0131\u011f\u0131nda q\u0131z\u0131lca \u00f6l\u00fcml\u0259rinin say\u0131 80 faiz azal\u0131b.
\nC\u0259mi bir ne\u00e7\u0259 on il \u0259vv\u0259l milyonlarla insan poliomielit x\u0259st\u0259liyinin qurban\u0131 olurdu – bu x\u0259st\u0259liy\u0259 yoluxanlar\u0131 ya iflic, ya da \u00f6l\u00fcm yaxalay\u0131rd\u0131. Haz\u0131rda poliomelit tamamil\u0259 yox olub.
\nPeyv\u0259ndl\u0259r icad olunana q\u0259d\u0259r d\u00fcnya bug\u00fcnk\u00fcnd\u0259n \u00e7ox-\u00e7ox t\u0259hl\u00fck\u0259liydi. M\u00fcasir peyv\u0259ndl\u0259r milyonlarla insan\u0131n h\u0259yat\u0131n\u0131 xilas edib.<\/p>\n
\n1. Biotech\/Phizer peyv\u0259ndi – Almaniya\/AB\u015e
\n2. Sputnik V peyv\u0259ndi – Rusiya
\n3. Moderna peyv\u0259ndi – AB\u015e
\n4. Oxford\/Astra Zeneca peyv\u0259ndi – \u0130ngilt\u0259r\u0259\/\u0130sve\u00e7
\n5. Sinovac peyv\u0259ndi \u2013 \u00c7in
\n6. Sinopharm – \u00c7in<\/p>\n
\n\u2022 Sputnik V peyv\u0259ndi \u2013 canl\u0131 adenovirus vektoru
\n\u2022 Moderna peyv\u0259ndi – mRNT \u0259sasl\u0131
\n\u2022 Oxford\/Astra Zeneca peyv\u0259ndi – canl\u0131 adenovirus vektoru
\n\u2022 Sinovac peyv\u0259ndi – \u0259n\u0259n\u0259vi
\n\u2022 Sinopharm peyv\u0259ndi \u2013 \u0259n\u0259n\u0259vi<\/p>\n
\n2.Sputnik V peyv\u0259ndi:\u00a0Canl\u0131 h\u00fcceyr\u0259 (Virusun da\u015f\u0131d\u0131\u011f\u0131 genetik materiallar\u0131n bir qismi ba\u015fqa virusun i\u00e7in\u0259 yerl\u0259\u015fdirilir v\u0259 insan b\u0259d\u0259nin\u0259 inyeksiya edilir);
\n3.Moderna peyv\u0259ndi:\u00a0Sintetik kod (Peyv\u0259nd insan qoluna inyeksiya edildikd\u0259 \u0259z\u0259l\u0259 h\u00fcceyr\u0259l\u0259ri virusu istehsal etm\u0259y\u0259 ba\u015flay\u0131r);
\n4.Oxford\/Astra Zeneca peyv\u0259ndi:\u00a0Canl\u0131 h\u00fcceyr\u0259 (Virusun da\u015f\u0131d\u0131\u011f\u0131 genetik material\u0131n bir qismi ba\u015fqa virusun i\u00e7in\u0259 yerl\u0259\u015fdiril\u0259r\u0259k insan b\u0259d\u0259nin\u0259 inyeksiya edilir);
\n5.Sinovac peyv\u0259ndi:\u00a0\u0130naktiv virus (toyuq yumurtas\u0131 v\u0259 ya toxuma kulturas\u0131nda \u00e7oxald\u0131lan h\u0259r\u0259k\u0259tsiz viruslar insan b\u0259d\u0259nin\u0259 inyeksiya edilir).<\/p>\n
\n\u2022 Sputnik V peyv\u0259ndi – 92%
\n\u2022 Moderna peyv\u0259ndi – 95%
\n\u2022 Oxford\/Astra Zeneca peyv\u0259ndi – 70%
\n\u2022 Sinovac peyv\u0259ndi – 92%<\/p>\n
\n\u2022 Sputnik V peyv\u0259ndi \u2013 4 (6 ay)
\n\u2022 Moderna peyv\u0259ndi – 20 (6 ay) \/ 4 (30 gun)
\n\u2022 Oxford\/Astra Zeneca peyv\u0259ndi – 4 (6 ay)
\n\u2022 Sinovac peyv\u0259ndi \u20132-8 (6 ay)<\/p>\n
\n65 ya\u015fdan yuxar\u0131 \u015f\u0259xsl\u0259r;
\nH\u00fcquq-m\u00fchafiz\u0259 orqanlar\u0131 t\u0259r\u0259find\u0259n \u0259ks-epidemik t\u0259dbirl\u0259r\u0259 c\u0259lb olunan hey\u0259t;
\n2-ci m\u0259rh\u0259l\u0259 – Tibbi c\u0259h\u0259td\u0259n y\u00fcks\u0259k risk qrupu (t\u0259n\u0259ff\u00fcs sistemi, hemodializ, \u015f\u0259k\u0259rli diabet, piyl\u0259nm\u0259 kimi xroniki x\u0259st\u0259likl\u0259ri olanlar);
\n-50 ya\u015f v\u0259 daha yuxar\u0131 \u0259n az bir xroniki x\u0259st\u0259liyi olan \u015f\u0259xsl\u0259r;
\n-T\u0259hsil v\u0259 sosial sektorda \u00e7al\u0131\u015fanlar, sosial m\u00fc\u0259ssis\u0259l\u0259rd\u0259 daimi ya\u015fayanlar, ASAN Xidm\u0259t v\u0259 DOST m\u0259rk\u0259zl\u0259ri, ictimai n\u0259qliyyat sektorunun, telekommunikasiya operatorlar\u0131 v\u0259 provayderl\u0259rinin v\u0259 po\u00e7t sah\u0259sind\u0259 birba\u015fa \u0259hali il\u0259 t\u0259masda olan i\u015f\u00e7il\u0259rin v\u0259 bank sektorunun birba\u015fa \u0259hali il\u0259 t\u0259masda olan hiss\u0259si;
\n-Y\u00fcks\u0259k riskli \u015f\u0259raitli i\u015fl\u0259rd\u0259 \u00e7al\u0131\u015fan (c\u0259miyy\u0259tin f\u0259aliyy\u0259ti \u00fc\u00e7\u00fcn h\u0259yat\u0131 vacib sah\u0259l\u0259rd\u0259 \u00e7al\u0131\u015fan \u2013 milli v\u0259 regional t\u0259hl\u00fck\u0259sizlik, \u0259dliyy\u0259, maliyy\u0259 v\u0259 s.) \u015f\u0259xsl\u0259r.<\/p>\n
\n\u2022 vaksin preparatlar\u0131n\u0131n effektivliyi (vaksinasiyadan sonra insan orqanizminin immun statusu h\u0259min infeksiyaya qar\u015f\u0131 m\u00fcqavim\u0259t g\u00f6st\u0259rm\u0259y\u0259 yet\u0259rli olanlar).
\n\u2022 vaksin preparat\u0131n\u0131n \u0259l\u00e7atanl\u0131\u011f\u0131<\/p>\n
\n\u2022 -Soyuq z\u0259ncir\u00bb \u015f\u0259raitin\u0259 uy\u011fun olaraq vaksinl\u0259rin \u00f6lk\u0259y\u0259 g\u0259tirilm\u0259si, saxlanmas\u0131 v\u0259 m\u0259nt\u0259q\u0259l\u0259r\u0259 \u00e7atd\u0131r\u0131lmas\u0131 \u00fc\u00e7\u00fcn t\u0259l\u0259b olunan x\u00fcsusi infrastruktur art\u0131q qurulmu\u015fdur.
\n\u2022 Vaksinasiya m\u0259nt\u0259q\u0259l\u0259rinin \u015f\u0259raiti \u2013 m\u0259nt\u0259q\u0259l\u0259rin t\u0259l\u0259b olunan l\u0259vazimatlarla t\u0259min olunmas\u0131, hey\u0259tin t\u0259liml\u0259ndirilm\u0259si v\u0259 dig\u0259r haz\u0131rl\u0131q t\u0259dbirl\u0259rinin h\u0259yata ke\u00e7irilib.<\/p>\n
\n\u00d6l\u00fcm\u0259 s\u0259b\u0259b olan postvaksinal f\u0259sadlara g\u00f6r\u0259 bird\u0259f\u0259lik m\u00fcavin\u0259t almaq h\u00fcququ olan ail\u0259 \u00fczvl\u0259rinin siyah\u0131s\u0131 v\u0259 h\u0259min m\u00fcavin\u0259tin h\u0259cmi m\u00fcvafiq icra hakimiyy\u0259ti orqan\u0131 t\u0259r\u0259find\u0259n m\u00fc\u0259yy\u0259n edilir.<\/p>\n